These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9353565)

  • 1. Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates.
    Nogusa H; Yano T; Kajiki M; Gonsho A; Hamana H; Okuno S
    Biol Pharm Bull; 1997 Oct; 20(10):1061-5. PubMed ID: 9353565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties.
    Nogusa H; Yano T; Okuno S; Hamana H; Inoue K
    Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1931-6. PubMed ID: 8575033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents.
    Nogusa H; Yamamoto K; Yano T; Kajiki M; Hamana H; Okuno S
    Biol Pharm Bull; 2000 May; 23(5):621-6. PubMed ID: 10823676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates.
    Nogusa H; Hamana H; Uchida N; Maekawa R; Yoshioka T
    Jpn J Cancer Res; 2000 Dec; 91(12):1333-8. PubMed ID: 11123434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates--systematic modification of peptide spacers.
    Nogusa H; Yano T; Kashima N; Yamamoto K; Okuno S; Hamana H
    Bioorg Med Chem Lett; 2000 Feb; 10(3):227-30. PubMed ID: 10698441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.
    Shiose Y; Kuga H; Ohki H; Ikeda M; Yamashita F; Hashida M
    Bioconjug Chem; 2009 Jan; 20(1):60-70. PubMed ID: 19090781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting.
    Sugahara S; Okuno S; Yano T; Hamana H; Inoue K
    Biol Pharm Bull; 2001 May; 24(5):535-43. PubMed ID: 11379776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cytocidal activity and glutathione-S-transferase inhibition using doxorubicin coupled to stereoisomers of glutathione with different substrate specificity.
    Hashizume Y; Asakura T; Oikawa T; Yamauchi T; Soda K; Ohkawa K
    Anticancer Drugs; 2001 Jul; 12(6):549-54. PubMed ID: 11460002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
    Takahashi H; Adachi K; Yamaguchi F; Teramoto A
    Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of carboxymethylpullulan as a novel carrier for targeting immune tissues.
    Masuda K; Sakagami M; Horie K; Nogusa H; Hamana H; Hirano K
    Pharm Res; 2001 Feb; 18(2):217-23. PubMed ID: 11405294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
    Ohkawa K; Hatano T; Tsukada Y; Matsuda M
    Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.
    Asakura T; Takahashi N; Takada K; Inoue T; Ohkawa K
    Anticancer Drugs; 1997 Feb; 8(2):199-203. PubMed ID: 9073316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of angiotensin II on the antitumor activity and cardiotoxicity of doxorubicin.
    Monti E; Paracchini L; Piccinini F; Rossi C; Formelli F
    Cancer Lett; 1990 Apr; 50(1):79-85. PubMed ID: 2353985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the sialyl Lewis X (SLe(x)) moiety on splenic accumulation of SLe(x)-carboxymethylpullulan conjugate.
    Horie K; Sakagami M; Kuramochi K; Ito T; Hamana H
    Microbiol Immunol; 2000; 44(5):401-4. PubMed ID: 10888360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
    Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
    Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
    Hatano T; Ohkawa K; Matsuda M
    Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer.
    Oyama T; Kawamura M; Abiko T; Izumi Y; Watanabe M; Kumazawa E; Kuga H; Shiose Y; Kobayashi K
    Oncol Rep; 2007 Mar; 17(3):653-9. PubMed ID: 17273747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialyl Lewis X-carboxymethylpullulan conjugate: a novel homing device to spleen and lymph nodes.
    Horie K; Sakagami M; Masuda K; Notoya M; Hamana H; Yoshikawa T; Hirano K
    Biol Pharm Bull; 2004 Aug; 27(8):1275-80. PubMed ID: 15305036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.
    Danesi R; Marchetti A; Bernardini N; La Rocca RV; Bevilacqua G; Del Tacca M
    Cancer Chemother Pharmacol; 1990; 26(6):403-8. PubMed ID: 2171795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
    BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.